Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM asthma effectiveness study
jRCT2031240008Phase 4Completed
- Sponsor
- GSK
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of fluticasone, umeclidinium and vilanterol in asthma (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough forced expiratory volume in 1 second at Week 24. Started May 2024; status: completed.
02
Drugs
fluticasoneumeclidiniumvilanterol
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2031240008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240008.